We are live on ! Find out more
MREO

Mereo BioPharma
MREO

58 hedge funds and large institutions have $43M invested in Mereo BioPharma in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 15 increasing their positions, 14 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 14

0.12% less ownership

Funds ownership: 9.85% → 9.73% (-0.12%)

5% less funds holding

Funds holding: 61 → 58 (-3)

7% less capital invested

Capital invested by funds: $46.2M → $43M (-$3.16M)

30% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 10

Holders
58
Holders Change
-3
Holders Change %
-4.92%
% of All Funds
0.92%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
15
Reduced
14
Closed
10
Calls
$54K
Puts
–
Net Calls
+$54K
Net Calls Change
+$48K

Top Buyers

Rank Fund Capital Flow
1
6CM
683 Capital Management
New York
+$1.69M
2
Millennium Management
Millennium Management
New York
+$1.07M
3
Citigroup
Citigroup
New York
+$1.02M
4
BFM
Boothbay Fund Management
New York
+$385K
5
JGC
J. Goldman & Co
New York
+$267K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$2.57M
2
AG
Artal Group
Luxembourg
-$1.13M
3
OCA
Octagon Capital Advisors
New York
-$750K
4
MAM
Monaco Asset Management
Monaco
-$660K
5
Renaissance Technologies
Renaissance Technologies
New York
-$307K
Name Holding Trade Value Shares
Change 		Change in
Stake
PFMU
26
Privium Fund Management (UK)
United Kingdom
$131K – – –
SSA
27
Schonfeld Strategic Advisors
New York
$114K +$4.14K +4,600 +3%
Geode Capital Management
28
Geode Capital Management
Massachusetts
$68.3K – – –
UBS Group
29
UBS Group
Switzerland
$68K -$29.1K -32,384 -25%
Jane Street
30
Jane Street
New York
$64.4K -$91.7K -101,869 -53%
FA
31
Forefront Analytics
Pennsylvania
$59.2K +$9.18K +10,200 +14%
CHAM
32
Clear Harbor Asset Management
Connecticut
$57.1K -$2.92K -3,246 -4%
WVP
33
Worth Venture Partners
New Jersey
$54.1K +$68.9K +76,513 New
SEI Investments
34
SEI Investments
Pennsylvania
$41.5K +$52.8K +58,718 New
Bessemer Group
35
Bessemer Group
New Jersey
$41K – – –
HSBC Holdings
36
HSBC Holdings
United Kingdom
$40.9K – – –
PI
37
PFG Investments
New York
$33.6K +$42.7K +47,500 New
Susquehanna International Group
38
Susquehanna International Group
Pennsylvania
$30.5K +$27K +29,989 +229%
Creative Planning
39
Creative Planning
Kansas
$27.1K +$11.2K +12,500 +48%
CC
40
Centiva Capital
New York
$17.8K – – –
OC
41
Oppenheimer & Co
New York
$17K – – –
OIA
42
OneDigital Investment Advisors
Kansas
$15.5K +$19.8K +21,962 New
Bank of America
43
Bank of America
North Carolina
$15K -$41.7K -46,347 -69%
LFAS
44
Level Four Advisory Services
Texas
$14.1K – – –
GSEP
45
Golden State Equity Partners
California
$10.2K +$13K +14,400 New
CL
46
CSS LLC
Illinois
$7.59K – – –
Morgan Stanley
47
Morgan Stanley
New York
$6.38K -$16.6K -18,430 -67%
Group One Trading
48
Group One Trading
Illinois
$5.75K -$33.2K -36,944 -82%
NFSG
49
Newbridge Financial Services Group
Florida
$4.95K +$2.7K +3,000 +75%
AAP
50
Arax Advisory Partners
Colorado
$2.83K – – –
1
2
3

MREO Hedge Fund Activity: Q1 2023 in Review

58 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q1 2023, worth a combined $43M — down 6.8% from $46.2M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of MREO and 7 opened new positions — a net loss of 3 holders — while 14 trimmed existing stakes and 15 added.

The largest buyer was 683 Capital Management, adding an estimated $1.69M. The largest seller was OrbiMed, cutting an estimated $2.57M.

  • 58 institutional investors held Mereo BioPharma (MREO) as of Q1 2023, down from 61 in Q4 2022.
  • Funds reported $43M of Mereo BioPharma stock for Q1 2023, down 6.8% quarter-over-quarter.
  • 7 funds opened new Mereo BioPharma positions in Q1 2023 and 10 closed out, a net change of -3 holders.
  • The largest Mereo BioPharma buyer in Q1 2023 was 683 Capital Management, an estimated $1.69M added.
  • The largest Mereo BioPharma seller in Q1 2023 was OrbiMed, an estimated $2.57M sold.

Based on aggregated 13F filings for Q1 2023.